The patient pathway for mild cognitive impairment due to Alzheimer’s disease in Asia: Current practices, barriers, and expert recommendations for optimization

Seong Hye Choi, SangYun Kim, Paulus Anam Ong, Ai‐Vyrn Chin, Jacqueline C. Dominguez, Christopher Chen, Vorapun Senanarong, Chaur Jong Hu, Manjari Tripathi, Vincent Mok, Gandan Jiang, Amitabh DashThe Journal of Prevention of Alzheimer s Disease 2025 · DOI

TL;DR

This study investigates the current patient journey for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) across Asia, highlighting significant regional disparities in diagnosis and treatment. It identifies key barriers to timely care and provides expert recommendations for optimizing pathways to prepare for the advent of new disease-modifying therapies (DMTs).

What Problem Does This Paper Address?

Alzheimer's disease (AD) is a growing global health concern, with increasing prevalence, particularly in Asia. The recent development of disease-modifying therapies (DMTs) that can slow disease progression, even in early stages like mild cognitive impairment (MCI), presents a critical need to understand and optimize the patient pathway. However, challenges in diagnosing MCI due to AD, especially in diverse Asian healthcare systems, remain. This paper addresses the gap in understanding the current landscape of MCI diagnosis and management across various Asian countries, identifying barriers to timely and effective care, and proposing solutions to ensure patients can benefit from emerging treatments.

Methods

The study employed a qualitative, semi-structured interview approach with 44 physicians (primarily neurologists) from eight Asian countries (Hong Kong, India, Indonesia, Korea, Malaysia, the Philippines, Singapore, Taiwan, and Thailand). Physicians were selected based on their experience in managing MCI due to AD. A discussion guide covered patient presentation, assessment, diagnosis, communication, treatment, follow-up, and future expectations. Responses were thematically analyzed, and quantitative data (e.g., proportions of physicians using specific tests) were presented alongside qualitative insights. Comparisons were made between Korea, which has a more advanced dementia care system, and other Asian regions.

Datasets

Not discussed in the paper. The study relies on physician interviews as its primary data source.

Key Insights and Ideas

  • Regional Disparities are Stark: The study reveals significant differences in MCI diagnosis and management across Asia. Korea, with its established National Dementia Plan, generally shows more prompt diagnosis and better access to diagnostic tools compared to other regions.
  • Barriers to Timely Diagnosis: Common barriers include low disease awareness among patients, delayed healthcare visits, neuroimaging backlogs, and insufficient neuropsychology resources. Access to advanced biomarker tests like amyloid PET and CSF analysis is particularly limited outside of Korea.
  • The Dawn of DMTs Requires Preparedness: The impending availability of anti-amyloid DMTs necessitates a proactive approach to optimize diagnostic pathways and healthcare system readiness. This includes ensuring access to confirmatory biomarker tests.
  • Patient Education is Crucial: A significant insight is the need for better patient and caregiver education about MCI and AD, to reduce stigma, improve understanding, and encourage proactive healthcare seeking.
  • The Role of Biomarkers is Evolving: While MRI is widely used, the study highlights the growing importance of amyloid biomarkers (PET, CSF, and emerging blood tests) for confirming AD pathology and guiding treatment decisions, especially with new DMTs.

Key Results

  • Physician Demographics: 44 physicians were interviewed, with a majority from Korea (54.5%) and most being neurologists (70.5%).
  • Patient Management: Physicians managed a median of 67.5 MCI patients per month, with 24.0-87.5% of these cases attributed to AD.
  • Diagnostic Tools: Brief neuropsychological assessments like the Mini-Mental State Examination (MMSE) were widely used (93.2%), considered essential by most. Comprehensive neuropsychological test batteries and amyloid PET were seldom conducted outside of Korea.
  • Neuroimaging: MRI was universally used (100%) and considered essential. CT scans were used by 59.1% of physicians.
  • Biomarker Use: Fluid biomarkers (blood/plasma and CSF) were seldom used. Amyloid PET was more accessible in Korea (33% of patients) than in other regions (5%).
  • Treatment: Nootropics and acetylcholinesterase inhibitors (AChEIs) were the primary pharmacological treatments. Non-pharmacological interventions, particularly lifestyle modifications, were almost universally recommended.
  • Barriers: Delayed healthcare visits, neuroimaging backlogs, and insufficient neuropsychology resources were key barriers. Limited access to amyloid biomarker tests was noted in regions other than Korea.
  • Recommendations: The study proposes optimizing screening, diagnosis, patient education, and healthcare system infrastructure to accommodate new DMTs.

Limitations and Future Work

The authors acknowledge several limitations:

  • Subjectivity: The study relies on physician self-reported data, which may be subject to recall bias or social desirability bias, and may not represent an objective measure of the situation.
  • Generalizability: The exclusion of physicians from mainland China and Japan limits the generalizability of findings to the entire Asian region. The response rate, while adequate, may not fully capture the diversity of clinical practices.
  • Limited Stakeholder Input: The study did not include patients, family members, or caregivers, whose perspectives are crucial for a holistic understanding.

Future work should focus on:

  • Qualitative Exploration: Deeper qualitative research to explore the underlying factors contributing to identified barriers.
  • Broader Stakeholder Inclusion: Incorporating the perspectives of patients, caregivers, and other healthcare professionals.
  • Objective Data Collection: Complementing physician reports with objective data on healthcare system capacity and patient outcomes.
  • Harmonization of Guidelines: Developing harmonized biomarker algorithms and best practices for diagnosis and treatment across Asia.
  • Reimbursement and Policy: Advocating for improved reimbursement policies for diagnostic tests and treatments.

Summary updated

Abstract

The survey findings showed that screening and diagnostic processes for mild cognitive impairment due to Alzheimer's disease in Asia require further optimization. Efforts should also be made to educate patients and caregivers, improve the diagnostic capabilities of primary and secondary healthcare providers, and reinforce cognitive screening services. The provision and reimbursement of confirmatory tests of amyloid burden should be expanded across the region to facilitate access to innovative disease-modifying therapies.
BibTeX
@article{choi2025patient,
  author = {Seong Hye Choi and SangYun Kim and Paulus Anam Ong and Ai‐Vyrn Chin and Jacqueline C. Dominguez and Christopher Chen and Vorapun Senanarong and Chaur Jong Hu and Manjari Tripathi and Vincent Mok and Gandan Jiang and Amitabh Dash},
  title = {{The patient pathway for mild cognitive impairment due to Alzheimer’s disease in Asia: Current practices, barriers, and expert recommendations for optimization}},
  journal = {The Journal of Prevention of Alzheimer s Disease},
  year = {2025},
  doi = {10.1016/j.tjpad.2025.100215},
}
Figure